Comparing two imaging methods for diagnosing pulmonary fibrosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the diagnostic value of 68Ga-FAPI PET/CT compared to 18F-FDG PET/CT in patients with pulmonary fibrosis. It aims to determine if 68Ga-FAPI, which targets activated fibroblasts, is more effective in assessing the severity of the disease and monitoring therapy response. The study will involve patients who have suspected or confirmed pulmonary fibrosis and will require their consent to participate. By conducting a head-to-head comparison, the research seeks to provide insights into the most effective imaging modality for this condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* suspected or confirmed pulmonary fibrosis patients;
* signed written consent.

Exclusion Criteria:

* pregnancy;
* breastfeeding;
* known allergy against FAPI
* any medical condition that in the opinion of the investigator may significantly interfere with study compliance

Where it's running

• Peking Union Medical College Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: Zhaohui Zhu, MD — Peking Union Medical College Hospital
• Study coordinator: Zhaohui Zhu, MD
• Email: 13611093752@163.com
• Phone: 86-13611093752

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AccuPulmo CT Portal for Detecting Pulmonary Fibrosis on Chest CT

  This study tests how well the AccuPulmo CT Portal can identify pulmonary fibrosis on existing chest CT scans from adults at Taichung Veterans General Hospital.

  Recruiting Taichung Veterans General Hospital · Taichung · NCT07761377

• Advanced imaging to see how immunosuppression affects lung fibrosis activity

  This trial will test whether immunosuppression changes PET and MRI measurements of active collagen deposition and tissue injury in people with non‑IPF interstitial lung disease who are starting treatment.

  Recruiting Phase 2 Massachusetts General Hospital · Boston, Massachusetts · NCT07572383

• 68Ga-NI-FAPI-04 PET/CT imaging to detect fibroblast activation in cancer, fibrotic, and heart diseases

  This test will see if an injected PET tracer called 68Ga-NI-FAPI-04 can better show fibroblast activation in people with tumors, pulmonary fibrosis, certain autoimmune vascular diseases, hypertrophic cardiomyopathy, or other cardiovascular conditions.

  Recruiting Phase 1/2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07464132

• Home monitoring for patients with pulmonary fibrosis

  This study tests if using home monitoring and video calls can help people with pulmonary fibrosis manage their condition as well as or better than regular clinic visits.

  Recruiting at 11 sites Erasmus Medical Center · Amsterdam and 10 other locations · NCT06883448

• Understanding genetic and environmental factors in pulmonary fibrosis

  This study looks at how genes and environmental factors affect pulmonary fibrosis to help understand the disease better for people who have it.

  Recruiting Royal College of Surgeons, Ireland · Dublin · NCT06702228

• Identifying biomarkers for progressive pulmonary fibrosis in lung disease patients

  This study is trying to find early signs that can help predict if adults with certain lung diseases will develop progressive pulmonary fibrosis over the next five years.

  Recruiting Amsterdam UMC, location VUmc · Amsterdam, North Holland · NCT06644144

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.